CN111518771A - 共表达抗CD19嵌合抗原受体和Nur77抑制分子的转基因淋巴细胞及其用途 - Google Patents
共表达抗CD19嵌合抗原受体和Nur77抑制分子的转基因淋巴细胞及其用途 Download PDFInfo
- Publication number
- CN111518771A CN111518771A CN202010195202.1A CN202010195202A CN111518771A CN 111518771 A CN111518771 A CN 111518771A CN 202010195202 A CN202010195202 A CN 202010195202A CN 111518771 A CN111518771 A CN 111518771A
- Authority
- CN
- China
- Prior art keywords
- lymphocyte
- nur77
- nucleic acid
- cells
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101100405118 Mus musculus Nr4a1 gene Proteins 0.000 title claims abstract description 85
- 101100405120 Xenopus laevis nr4a1 gene Proteins 0.000 title claims abstract description 85
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 title claims abstract description 83
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 74
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 50
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 34
- 230000002401 inhibitory effect Effects 0.000 title description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 101
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 230000003834 intracellular effect Effects 0.000 claims abstract description 22
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims abstract description 11
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 10
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 241000713666 Lentivirus Species 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- 230000030279 gene silencing Effects 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 16
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 9
- 239000004055 small Interfering RNA Substances 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 54
- 210000004881 tumor cell Anatomy 0.000 abstract description 47
- 230000002147 killing effect Effects 0.000 abstract description 38
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 31
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 23
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 23
- 238000000338 in vitro Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 15
- 230000005909 tumor killing Effects 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 11
- 108020002144 NR4 subfamily Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 8
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 238000011789 NOD SCID mouse Methods 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241000167854 Bourreria succulenta Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000019693 cherries Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 2
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108010068380 arginylarginine Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- YEELWQSXYBJVSV-UWJYBYFXSA-N Ala-Cys-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YEELWQSXYBJVSV-UWJYBYFXSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 description 1
- RUXQNKVQSKOOBS-JURCDPSOSA-N Ala-Phe-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RUXQNKVQSKOOBS-JURCDPSOSA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- DIIGDGJKTMLQQW-IHRRRGAJSA-N Arg-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N DIIGDGJKTMLQQW-IHRRRGAJSA-N 0.000 description 1
- 108010051330 Arg-Pro-Gly-Pro Proteins 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 1
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 1
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 1
- FQHBAQLBIXLWAG-DCAQKATOSA-N Asp-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N FQHBAQLBIXLWAG-DCAQKATOSA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 108010024755 CTL019 chimeric antigen receptor Proteins 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- SWJYSDXMTPMBHO-FXQIFTODSA-N Cys-Pro-Ser Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SWJYSDXMTPMBHO-FXQIFTODSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 1
- TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 1
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 1
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 1
- BUAKRRKDHSSIKK-IHRRRGAJSA-N Glu-Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BUAKRRKDHSSIKK-IHRRRGAJSA-N 0.000 description 1
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 1
- UQULNJAARAXSPO-ZCWPNWOLSA-N Glu-Thr-Thr-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UQULNJAARAXSPO-ZCWPNWOLSA-N 0.000 description 1
- HGJREIGJLUQBTJ-SZMVWBNQSA-N Glu-Trp-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O HGJREIGJLUQBTJ-SZMVWBNQSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 1
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- ZWRDOVYMQAAISL-UWVGGRQHSA-N Gly-Met-Lys Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCCN ZWRDOVYMQAAISL-UWVGGRQHSA-N 0.000 description 1
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 1
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 1
- ZVXMEWXHFBYJPI-LSJOCFKGSA-N Gly-Val-Ile Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZVXMEWXHFBYJPI-LSJOCFKGSA-N 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 1
- HUWYGQOISIJNMK-SIGLWIIPSA-N Ile-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HUWYGQOISIJNMK-SIGLWIIPSA-N 0.000 description 1
- KLJKJVXDHVUMMZ-KKPKCPPISA-N Ile-Phe-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N KLJKJVXDHVUMMZ-KKPKCPPISA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- MPSBSKHOWJQHBS-IHRRRGAJSA-N Leu-His-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)O)N MPSBSKHOWJQHBS-IHRRRGAJSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 1
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 1
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 1
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 1
- KPJJOZUXFOLGMQ-CIUDSAMLSA-N Lys-Asp-Asn Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N KPJJOZUXFOLGMQ-CIUDSAMLSA-N 0.000 description 1
- UETQMSASAVBGJY-QWRGUYRKSA-N Lys-Gly-His Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 UETQMSASAVBGJY-QWRGUYRKSA-N 0.000 description 1
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 1
- OIYWBDBHEGAVST-BZSNNMDCSA-N Lys-His-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OIYWBDBHEGAVST-BZSNNMDCSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- GOVDTWNJCBRRBJ-DCAQKATOSA-N Lys-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N GOVDTWNJCBRRBJ-DCAQKATOSA-N 0.000 description 1
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 1
- DBOMZJOESVYERT-GUBZILKMSA-N Met-Asn-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N DBOMZJOESVYERT-GUBZILKMSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 208000025696 NK cell deficiency Diseases 0.000 description 1
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
- FSPGBMWPNMRWDB-AVGNSLFASA-N Phe-Cys-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N FSPGBMWPNMRWDB-AVGNSLFASA-N 0.000 description 1
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- LCRSGSIRKLXZMZ-BPNCWPANSA-N Pro-Ala-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LCRSGSIRKLXZMZ-BPNCWPANSA-N 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 1
- PTLOFJZJADCNCD-DCAQKATOSA-N Pro-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 PTLOFJZJADCNCD-DCAQKATOSA-N 0.000 description 1
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 1
- DRKAXLDECUGLFE-ULQDDVLXSA-N Pro-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O DRKAXLDECUGLFE-ULQDDVLXSA-N 0.000 description 1
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 description 1
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 1
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 1
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- PXQUBKWZENPDGE-CIQUZCHMSA-N Thr-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N PXQUBKWZENPDGE-CIQUZCHMSA-N 0.000 description 1
- YOSLMIPKOUAHKI-OLHMAJIHSA-N Thr-Asp-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YOSLMIPKOUAHKI-OLHMAJIHSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- GMXIJHCBTZDAPD-QPHKQPEJSA-N Thr-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N GMXIJHCBTZDAPD-QPHKQPEJSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
- JLNMFGCJODTXDH-WEDXCCLWSA-N Thr-Lys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O JLNMFGCJODTXDH-WEDXCCLWSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- BZTSQFWJNJYZSX-JRQIVUDYSA-N Thr-Tyr-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O BZTSQFWJNJYZSX-JRQIVUDYSA-N 0.000 description 1
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- NXQAOORHSYJRGH-AAEUAGOBSA-N Trp-Gly-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 NXQAOORHSYJRGH-AAEUAGOBSA-N 0.000 description 1
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 1
- OOEUVMFKKZYSRX-LEWSCRJBSA-N Tyr-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OOEUVMFKKZYSRX-LEWSCRJBSA-N 0.000 description 1
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- CKHQKYHIZCRTAP-SOUVJXGZSA-N Tyr-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CKHQKYHIZCRTAP-SOUVJXGZSA-N 0.000 description 1
- CVXURBLRELTJKO-BWAGICSOSA-N Tyr-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O CVXURBLRELTJKO-BWAGICSOSA-N 0.000 description 1
- BSCBBPKDVOZICB-KKUMJFAQSA-N Tyr-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BSCBBPKDVOZICB-KKUMJFAQSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- ILMVQSHENUZYIZ-JYJNAYRXSA-N Val-Met-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N ILMVQSHENUZYIZ-JYJNAYRXSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 1
- 108010081404 acein-2 Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提出了一种转基因淋巴细胞、一种构建体和一种治疗癌症的治疗组合物,该转基因淋巴细胞的细胞Nur77被沉默以及表达嵌合抗原受体。其中,所述嵌合抗原受体包括:胞外区,所述胞外区包括单链抗体的重链可变区和轻链可变区,所述单链抗体特异性识别抗原CD19;跨膜区,所述跨膜区与所述胞外区相连,并且嵌入到所述T淋巴细胞的细胞膜中;胞内区,所述胞内区与所述跨膜区相连,并且所述胞内区包括CD28的胞内段以及CD3ζ链。该转基因淋巴细胞具有耐受能力强的特性,对肿瘤细胞的杀伤能力显著增强,尤其高表达CD19的肿瘤具有显著的定向杀伤作用。
Description
技术领域
本发明涉及生物医药领域,具体地,本发明涉及一种T淋巴细胞、一种慢病毒、一种转基因淋巴细胞、一种构建体和一种用于治疗癌症的治疗组合物。
背景技术
嵌合抗原受体T细胞(CAR T细胞)是指将识别肿瘤相关抗原(tumor associatedantigen,TAA)的scFv和胞内信号域“免疫受体酪氨酸活化基序(immune receptortyrosine-based activation motifs,ITAM,通常为CD3ζ或FcεRIγ)”在体外进行基因重组,生成重组质粒,再在体外通过转染技术转染到患者的T细胞,使患者T细胞表达肿瘤抗原受体,转染后经过纯化和大规模扩增后的T细胞CAR T细胞在体内、外都具有对特定肿瘤抗原高度亲和性及对抗原负载细胞高效杀伤特性。CAR T细胞技术在白血病、淋巴瘤、黑色素瘤、脑胶质瘤等恶性肿瘤治疗中均显示出良好的抗肿瘤效应。
使用嵌合抗原受体(CAR)修饰的自体T细胞(CART)疗法上的近来进展提示,在利用免疫系统治疗B细胞恶性病和其它癌症方面显示出强大作用,其中所述CAR T疗法依赖于将T细胞重新定向于癌细胞例如B细胞恶性病上的合适细胞表面分子。鼠源CART19(即“CTL019”)的临床结果已经表现出有希望在罹患CLL的患者和儿童ALL中建立完全缓解。除了在遗传修饰T细胞上的嵌合抗原受体能够识别和破坏所靶向的细胞外,成功的治疗性T细胞疗法还需要具有增殖和长时间维持的能力、以及监控白血病细胞逃逸的能力。
但是,在目前CAR T生物治疗的临床研究也发现,T细胞的变异性质(无论这是无能(anergy)、抑制或是耗竭的结果)对CAR转化的T细胞的性能产生影响,而对此影响,本领域技术人员在目前可以施予的控制是有限的。
目前,减少CAR T细胞的耗竭是CAR T临床研究和治疗中亟待解决的重要问题。
发明内容
Nur77是孤儿核受体超家族的成员之一,作为转录因子参与了包括细胞增殖、分化、凋亡以及代谢和炎症等多种生物学调控过程。已有研究证实减少Nur77表达可以减少T细胞耐受。据此,发明人提出了一种提高CAR转化的患者T细胞持续存在并维持响应于CAR抗原的可能的解决办法,即在向T细胞转染抗CD19的嵌合抗原受体的同时也敲低T细胞中的Nur77的表达,以此减少T细胞耗竭,提高抗CD19的嵌合抗原受体T细胞对肿瘤的抑制杀伤作用。
在本发明的第一方面,本发明提出了一种T淋巴细胞。根据本发明的实施例,所述T淋巴细胞的Nur77被沉默;以及表达嵌合抗原受体,其中,所述嵌合抗原受体包括:胞外区,所述胞外区包括单链抗体的重链可变区和轻链可变区,所述单链抗体特异性识别抗原CD19;跨膜区,所述跨膜区与所述胞外区相连,并且嵌入到所述T淋巴细胞的细胞膜中;胞内区,所述胞内区与所述跨膜区相连,并且所述胞内区包括CD28的胞内段以及CD3ζ链。根据本发明的实施例,本发明实施例的T淋巴细胞具有抵抗肿瘤细胞介导的免疫抑制的特性,耐受性显著提高,对肿瘤细胞的杀伤能力显著增强,尤其对高表达CD19的肿瘤细胞具有显著的定向杀伤作用。
在本发明的第二方面,本发明提出了一种慢病毒。根据本发明的实施例,所述慢病毒携带下列核酸分子:编码嵌合抗原受体的核酸分子,所述嵌合抗原受体具有SEQ ID NO:1所示的氨基酸序列,所述编码嵌合抗原受体的核酸分子具有SEQ ID NO:2所示的核苷酸序列。
在本发明的第三方面,本发明提出了一种慢病毒。根据本发明的实施例,所述慢病毒携带下列核酸分子:沉默Nur77的核酸分子,所述沉默Nur77的核酸分子的核苷酸序列为选自SEQ ID NO:3~6的至少之一,优选,所述沉默Nur77的核酸分子的核苷酸序列为SEQ IDNO:3所示。
MLLLVTSLLLCELPHPAFLLIPDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:1)。
ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCAGACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCGTACACGTTCGGAGGGGGGACTAAGTTGGAAATAACAGGCTCCACCTCTGGATCCGGCAAGCCCGGATCTGGCGAGGGATCCACCAAGGGCGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTCAGGGGTCTCATTACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAATATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGGTGGTAGCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCGGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGGGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC(SEQ ID NO:2)。
CCCGGCTCCTTCAAGTTCGAGGACTTGAATTCAAGTCCTCGAACTTGAAGGAGTT TTT(SEQ IDNO:3)。
CCCGGGATTGACAGTATCCTGGCCTTGAATTCAAGGCCAGGATACTGTCAATCTTTTT(SEQ ID NO:4)。
CCCGGTGGTGAAGGAAGTTGTCCGAAGAATTCTTCGGACAACTTCCTTCACCATTTTT(SEQ ID NO:5)。
CCCGGGCTACACAGGAGAGTTTGACAGAATTCTGTCAAACTCTCCTGTGTAGCTTTTT(SEQ ID NO:6)。
发明人发现,携带具有SEQ ID NO:3所示核苷酸序列的慢病毒导入淋巴细胞后,对Nur77沉默效果更佳。
根据本发明的实施例,将本发明的慢病毒导入淋巴细胞所得的转基因淋巴细胞,其具有抵抗肿瘤细胞介导的免疫抑制的特性,耐受能力显著增强,对肿瘤细胞的杀伤能力显著增强,尤其对高表达CD19的肿瘤细胞具有显著的定向杀伤作用。
在本发明的第四方面,本发明提出了一种慢病毒。根据本发明的实施例,所述慢病毒携带含有SEQ ID NO:7或8所示的核苷酸序列。
表达CD19 CAR的核酸的核苷酸序列:
ttggaagggctaattcactcccaaagaagacaagatatccttgatctgtggatctaccacacacaaggctacttccctgattagcagaactacacaccagggccaggggtcagatatccactgacctttggatggtgctacaagctagtaccagttgagccagataaggtagaagaggccaataaaggagagaacaccagcttgttacaccctgtgagcctgcatgggatggatgacccggagagagaagtgttagagtggaggtttgacagccgcctagcatttcatcacgtggcccgagagctgcatccggagtacttcaagaactgctgatatcgagcttgctacaagggactttccgctggggactttccagggaggcgtggcctgggcgggactggggagtggcgagccctcagatcctgcatataagcagctgctttttgcctgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcagggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacaggatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttagacaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacgctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttggggttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctggatggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggaggcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaaccccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatctcgacggtatcgatgtcgacgataagctttgcaaagatggataaagttttaaacagagaggaatctttgcagctaatggaccttctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgaaccggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccagaacacaggtaagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggcccttgcgtgccttgaattacttccactggctgcagtacgtgattcttgatcccgagcttcgggttggaagtgggtgggagagttcgaggccttgcgcttaaggagccccttcgcctcgtgcttgagttgaggcctggcctgggcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcctgtctcgctgctttcgataagtctctagccatttaaaatttttgatgacctgctgcgacgctttttttctggcaagatagtcttgtaaatgcgggccaagatctgcacactggtatttcggtttttggggccgcgggcggcgacggggcccgtgcgtcccagcgcacatgttcggcgaggcggggcctgcgagcgcggccaccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcctcgcgccgccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgcgtgagcggaaagatggccgcttcccggccctgctgcagggagctcaaaatggaggacgcggcgctcgggagagcgggcgggtgagtcacccacacaaaggaaaagggcctttccgtcctcagccgtcgcttcatgtgactccacggagtaccgggcgccgtccaggcacctcgattagttctcgagcttttggagtacgtcgtctttaggttggggggaggggttttatgcgatggagtttccccacactgagtgggtggagactgaagttaggccagcttggcacttgatgtaattctccttggaatttgccctttttgagtttggatcttggttcattctcaagcctcagacagtggttcaaagtttttttcttccatttcaggtgtcgtgaggaatttcgacatttaaatttaattaatctcgacggtatcggttaacttttaaaagaaaaggggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttccgatcacgagactagcctcgaggtttaaacgaattcatgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccagacatccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagggcaagtcaggacattagtaaatatttaaattggtatcagcagaaaccagatggaactgttaaactcctgatctaccatacatcaagattacactcaggagtcccatcaaggttcagtggcagtgggtctggaacagattattctctcaccattagcaacctggagcaagaagatattgccacttacttttgccaacagggtaatacgcttccgtacacgttcggaggggggactaagttggaaataacaggctccacctctggatccggcaagcccggatctggcgagggatccaccaagggcgaggtgaaactgcaggagtcaggacctggcctggtggcgccctcacagagcctgtccgtcacatgcactgtctcaggggtctcattacccgactatggtgtaagctggattcgccagcctccacgaaagggtctggagtggctgggagtaatatggggtagtgaaaccacatactataattcagctctcaaatccagactgaccatcatcaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgatgacacagccatttactactgtgccaaacattattactacggtggtagctatgctatggactactggggtcaaggaacctcagtcaccgtctcctcagcggccgcaattgaagttatgtatcctcctccttacctagacaatgagaagagcaatggaaccattatccatgtgaaagggaaacacctttgtccaagtcccctatttcccggaccttctaagcccttttgggtgctggtggtggttgggggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagcaggctcctgcacagtgactacatgaacatgactccccgccgccccgggcccacccgcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctccagagtgaagttcagcaggagcgcagacgcccccgcgtaccagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgcactagtaaaattgtcgctcctgtcaaacaaactcttaactttgatttactcaaactggctggggatgtagaaagcaatccaggtccagctagcatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaacatatgataatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaagctgacgtcctttccatggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcatcggtacgtatggccaggtacctttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagcatctagaattaattccgtgtattctatagtgtcacctaaatcgtatgtgtatgatacataaggttatgtattaattgtagccgcgttctaacgacaatatgtacaagcctaattgtgtagcatctggcttactgaagcagaccctatcatctctctcgtaaactgccgtcagagtcggtttggttggacgaaccttctgagtttctggtaacgccgtcccgcacccggaaatggtcagcgaaccaatcagcagggtcatcgctagccagatcctctacgccggacgcatcgtggccggcatcaccggcgccacaggtgcggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcgccacttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccccgtggccgggggactgttgggcgccatctccttgcatgcaccattccttgcggcggcggtgctcaacggcctcaacctactactgggctgcttcctaatgcaggagtcgcataagggagagcgtcgaatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagcattgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggaagcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagcttggacacaagacaggcttgcgagatatgtttgagaataccactttatcccgcgtcagggagaggcagtgcgtaaaaagacgcggactcatgtgaaatactggtttttagtgcgccagatctctataatctcgcgcaacctattttcccctcgaacactttttaagccgtagataaacaggctgggacacttcacatgagcgaaaaatacatcgtcacctgggacatgttgcagatccatgcacgtaaactcgcaagccgactgatgccttctgaacaatggaaaggcattattgccgtaagccgtggcggtctgtaccgggtgcgttactggcgcgtgaactgggtattcgtcatgtcgataccgtttgtatttccagctacgatcacgacaaccagcgcgagcttaaagtgctgaaacgcgcagaaggcgatggcgaaggcttcatcgttattgatgacctggtggataccggtggtactgcggttgcgattcgtgaaatgtatccaaaagcgcactttgtcaccatcttcgcaaaaccggctggtcgtccgctggttgatgactatgttgttgatatcccgcaagatacctggattgaacagccgtgggatatgggcgtcgtattcgtcccgccaatctccggtcgctaatcttttcaacgcctggcactgccgggcgttgttctttttaacttcaggcgggttacaatagtttccagtaagtattctggaggctgcatccatgacacaggcaaacctgagcgaaaccctgttcaaaccccgctttaaacatcctgaaacctcgacgctagtccgccgctttaatcacggcgcacaaccgcctgtgcagtcggcccttgatggtaaaaccatccctcactggtatcgcatgattaaccgtctgatgtggatctggcgcggcattgacccacgcgaaatcctcgacgtccaggcacgtattgtgatgagcgatgccgaacgtaccgacgatgatttatacgatacggtgattggctaccgtggcggcaactggatttatgagtgggccccggatctttgtgaaggaaccttacttctgtggtgtgacataattggacaaactacctacagagatttaaagctctaaggtaaatataaaatttttaagtgtataatgtgttaaactactgattctaattgtttgtgtattttagattccaacctatggaactgatgaatgggagcagtggtggaatgcctttaatgaggaaaacctgttttgctcagaagaaatgccatctagtgatgatgaggctactgctgactctcaacattctactcctccaaaaaagaagagaaaggtagaagaccccaaggactttccttcagaattgctaagttttttgagtcatgctgtgtttagtaatagaactcttgcttgctttgctatttacaccacaaaggaaaaagctgcactgctatacaagaaaattatggaaaaatattctgtaacctttataagtaggcataacagttataatcataacatactgttttttcttactccacacaggcatagagtgtctgctattaataactatgctcaaaaattgtgtacctttagctttttaatttgtaaaggggttaataaggaatatttgatgtatagtgccttgactagagatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacacctccccctgaacctgaaacataaaatgaatgcaattgttgttgttaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggatcaactggataactcaagctaaccaaaatcatcccaaacttcccaccccataccctattaccactgccaattacctagtggtttcatttactctaaacctgtgattcctctgaattattttcattttaaagaaattgtatttgttaaatatgtactacaaacttagtag(SEQ ID NO:7)
沉默Nur77的核酸的核苷酸序列:
gacattgattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcagggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacaggatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttagacaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccggccgctgatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacgctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttggggttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctggatggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggaggcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaaccccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatcggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacagggacagcagagatccagtttggttagtaccgggcccgctctagagatccgacgcgccatctctaggcccgcgccggccccctcgcacagacttgtgggagaagctcggctactcccctgccccggttaatttgcatataatatttcctagtaactatagaggcttaatgtgcgataaaagacagataatctgttctttttaatactagctacattttacatgataggcttggatttctataacttcgtatagcatacattatacgaagttatacatgtcacaaaaggaaactcaccctaactgtaaagtaattgtgtgttttgagactataaatatcccttggagaaaagccttgttaaccccggctccttcaagttcgaggacttgaattcaagtcctcgaacttgaaggagtttttctcgagtactaggatccattaggcggccgcgtggataaccgtattaccgccatgcattagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctggtttagtgaaccgtcagatccgctagcgctaccggtcgccaccatggtgagcaagggcgaggaggataacatggccatcatcaaggagttcatgcgcttcaaggtgcacatggagggctccgtgaacggccacgagttcgagatcgagggcgagggcgagggccgcccctacgagggcacccagaccgccaagctgaaggtgaccaagggtggccccctgcccttcgcctgggacatcctgtcccctcagttcatgtacggctccaaggcctacgtgaagcaccccgccgacatccccgactacttgaagctgtccttccccgagggcttcaagtgggagcgcgtgatgaacttcgaggacggcggcgtggtgaccgtgacccaggactcctccctgcaggacggcgagttcatctacaaggtgaagctgcgcggcaccaacttcccctccgacggccccgtaatgcagaagaagaccatgggctgggaggcctcctccgagcggatgtaccccgaggacggcgccctgaagggcgagatcaagcagaggctgaagctgaaggacggcggccactacgacgctgaggtcaagaccacctacaaggccaagaagcccgtgcagctgcccggcgcctacaacgtcaacatcaagttggacatcacctcccacaacgaggactacaccatcgtggaacagtacgaacgcgccgagggccgccactccaccggcggcatggacgagctgtacaagtaagaattcgtcgagggacctaataacttcgtatagcatacattatacgaagttatacatgtttaagggttccggttccactaggtacaattcgatatcaagcttatcgataatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcatcgataccgtcgacctcgatcgagacctagaaaaacatggagcaatcacaagtagcaatacagcagctaccaatgctgattgtgcctggctagaagcacaagaggaggaggaggtgggttttccagtcacacctcaggtacctttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatatccttgatctgtggatctaccacacacaaggctacttccctgattggcagaactacacaccagggccagggatcagatatccactgacctttggatggtgctacaagctagtaccagttgagcaagagaaggtagaagaagccaatgaaggagagaacacccgcttgttacaccctgtgagcctgcatgggatggatgacccggagagagaagtattagagtggaggtttgacagccgcctagcatttcatcacatggcccgagagctgcatccggactgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagcatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctgcttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgcttagggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgtt(SEQ ID NO:8)。
发明人发现,将沉默Nur77的核酸分子和过表达CD19 CAR的核酸分子构建在一个慢病毒载体上,慢病毒包装效率会显著降低。根据本发明的实施例,沉默Nur77的载体用来表达shRNA的慢病毒载体pSicoR(SEQ ID NO:8所示的核苷酸序列为携带shRNA的慢病毒载体pSicoR序列),而表达CD19 CAR的载体是用于目的基因过表达的慢病毒载体pWPXLd(SEQID NO:7所示的核苷酸序列为携带表达CD19 CAR核酸的慢病毒载体pSicoR序列),分别包装慢病毒后,同时感染T细胞,再筛选双阳性的T细胞,双阳性率可以达到70%以上。
根据本发明的实施例,将本发明的慢病毒导入淋巴细胞所得的转基因淋巴细胞,其具有抵抗肿瘤细胞介导的免疫抑制的特性,耐受能力显著增强,对肿瘤细胞的杀伤能力显著增强,尤其对高表达CD19的肿瘤细胞具有显著的定向杀伤作用。
在本发明的第五方面,本发明提出了一种转基因淋巴细胞。根据本发明的实施例,所述淋巴细胞Nur77被沉默;以及表达嵌合抗原受体,所述嵌合抗原受体包括:胞外区,所述胞外区包括抗体的重链可变区和轻链可变区,所述抗体能够与肿瘤抗原特异性结合;跨膜区;以及胞内区,所述胞内区包括免疫共刺激分子胞内段,其中,所述抗体为单链抗体,所述肿瘤抗原为CD19。发明人惊奇的发现,细胞Nur77被沉默和表达抗CD19的嵌合抗原受体的淋巴细胞的耐受能力以及在肿瘤病人体内的对肿瘤细胞的特异性杀伤能力大大提高,尤其对高表达CD19的肿瘤细胞具有显著的定向杀伤作用。
根据本发明的实施例,上述转基因淋巴细胞还可以具有下列附加技术特征至少之一:
根据本发明的实施例,所述淋巴细胞细胞表面Nur77被沉默是通过shRNA、反义核酸、核酶、显性负突变、CRISPR和锌指核酸酶至少之一实现的。根据本发明的实施例,本发明实施例的淋巴细胞的Nur77的成功沉默,可显著提高本发明实施例的淋巴细胞耐受性,进一步提高了转基因淋巴细胞对肿瘤细胞的定向杀伤作用。
根据本发明的实施例,所述免疫共刺激分子胞内段独立地选自4-1BB、OX-40、CD40L、CD27、CD30、CD28以及他们的衍生物的至少一种。本发明实施例的免疫共刺激分子胞内段的表达以及细胞Nur77的沉默的联合,使得本发明实施例的转基因淋巴细胞的耐受能力以及对肿瘤的定向杀伤作用更加显著。
根据本发明的实施例,所述淋巴细胞细胞Nur77被沉默是通过shRNA实现的。本发明实施例的shRNA具有高效、特异性的沉默Nur77的作用,Nur77的成功沉默,使得本发明实施例的转基因淋巴细胞在肿瘤病人体内的耐受能力得到进一步提高,配合嵌合抗原受体的抗原靶向性,使得本发明实施例的转基因淋巴细胞对肿瘤的定向杀伤作用效果更加显著。
根据本发明的实施例,所述免疫共刺激分子胞内段是4-1BB或CD28的胞内段。本发明中的转基因淋巴细胞的嵌合抗原受体的免疫共刺激分子胞内段是CD28或者4-1BB的胞内段。根据本发明的实施例,免疫共刺激分子胞内段是CD28或者4-1BB的胞内段,进一步增强了本发明实施例的转基因淋巴细胞的定向杀伤作用。
根据本发明的实施例,所述淋巴细胞是CD3+T淋巴细胞或自然杀伤细胞或自然杀伤T细胞。本发明实施例的上述淋巴细胞的细胞Nur77被沉默,同时表达抗原特异性的嵌合抗原受体,如本发明的实施例的CD19抗原特异性的嵌合抗原受体,上述淋巴细胞的细胞免疫杀伤作用的靶向性更强,在肿瘤病人体内的耐受得到进一步提高,对肿瘤的定向杀伤作用效果更加显著。
在本发明的第六方面,本发明提出了一种构建体。根据本发明的实施例,所述构建体包括:第一核酸分子,所述第一核酸分子编码嵌合抗原受体;以及第二核酸分子,所述第二核酸分子沉默Nur77。其中,所述嵌合抗原受体如前所述。根据本发明的实施例,本发明实施例的构建体成功导入本发明实施例的淋巴细胞后,可有效沉默细胞Nur77和表达抗原特异性的嵌合抗原受体,从而本发明实施例的淋巴细胞对肿瘤细胞,尤其是高表达CD19的肿瘤细胞的定向杀伤作用更加显著。
根据本发明的实施例,上述构建体还可以进一步包括下列附加技术特征至少之一:
根据本发明的实施例,其特征在于所述第一核酸分子与所述第二核酸分子被设置在前面所述的淋巴细胞中沉默细胞Nur77和表达所述嵌合抗原受体。根据本发明的实施例,成功设置了上述第一核酸分子以及第二核酸分子的淋巴细胞,其淋巴细胞的Nur77被成功沉默,同时在淋巴细胞表面成功表达了抗原特异性嵌合抗原受体,如本发明实施例的CD19特异性的嵌合抗原受体,其具有杀伤力更强和特异性更强的肿瘤杀伤效果。
根据本发明的实施例,所述构建体进一步包括:第一启动子,所述第一启动子与所述第一核酸分子可操作地连接;以及第二启动子,所述第二启动子与所述第二核酸分子可操作地连接。根据本发明的实施例,第一启动子以及第二启动子的引入,使得第一核酸分子以及第二核酸分子分别独立的表达,有效保证了嵌合抗原受体抗原靶向性的生物学作用及以有效沉默了Nur77,使得本发明实施例的淋巴细胞的靶向作用更强,对肿瘤的杀伤作用,尤其对高表达CD19的肿瘤细胞的定向杀伤更加显著。
根据本发明的实施例,所述第一启动子、所述第二启动子分别独立地选自U6,H1,CMV,EF-1,LTR,RSV启动子。根据本发明的实施例,本发明实施例的上述启动子具有启动效率高、特异性强的特点,从而保证了细胞Nur77的高效沉默和嵌合抗原受体的高效表达,从而本发明实施例的淋巴细胞的耐受和生存能力大大提高,对肿瘤的定向杀伤效果更加显著。
根据本发明的实施例,所述构建体的载体是非致病性病毒载体。非致病性病毒载体的引入大大提高了构建体在淋巴细胞中的复制和扩增效率,从而大大提高了细胞Nur77的沉默和嵌合抗原受体在淋巴细胞中的高效表达,使得淋巴细胞耐受和生存能力大大提高,淋巴细胞的靶向作用进一步增强,对肿瘤细胞的杀伤作用更加显著。
根据本发明的实施例,所述病毒载体包括选自反转录病毒载体、慢病毒载体或腺病毒相关病毒载体的至少之一。本发明实施例的病毒的载体在病毒包装和感染过程中,病毒感染范围广泛,既可感染终末分化细胞,又可感染处于分裂期的细胞,其基因组既可整合到宿主染色体,又可游离在宿主染色体之外,从而可实现广谱而高效的感染效率,细胞Nur77高效沉默和嵌合抗原受体在淋巴细胞中的高效表达,使得本发明实施例的淋巴细胞的耐受和生存能力大大提高,淋巴细胞的靶向作用进一步增强,对肿瘤细胞,尤其对高表达CD19的肿瘤细胞的定向杀伤作用更加显著。
在本发明的第七方面,本发明提出了一种制备前面所述的T淋巴细胞或者转基因淋巴细胞的方法。根据本发明的实施例,所述方法包括:将前面所述的构建体或者前面所述的慢病毒引入到淋巴细胞中或者T淋巴细胞。所述构建体或慢病毒成功引入上述淋巴细胞或者T淋巴细胞中,实现了淋巴细胞的细胞Nur77被沉默和嵌合抗原受体的表达,从而本发明实施例的制备方法制备的转基因淋巴细胞或T淋巴细胞在肿瘤病人体内和体外的存活能力大大提高,转基因淋巴细胞或T淋巴细胞对肿瘤细胞,尤其是对高表达CD19的肿瘤细胞的靶向杀伤作用更强。
在本发明的第八方面,本发明提出了一种用于治疗癌症的治疗组合物。根据本发明的实施例,所述治疗组合物包括:上述构建体、慢病毒、T淋巴细胞或者转基因淋巴细胞。上述任意一种治疗组合物的组成均可实现转基因淋巴细胞或T淋巴细胞的Nur77的沉默和嵌合抗原受体在转基因淋巴细胞或T淋巴细胞中的高效表达,从而使得所得转基因淋巴细胞或T淋巴细胞具有显著的抵抗肿瘤细胞介导的免疫抑制,在肿瘤病人体外和体内的耐受和存活能力大大提高,转基因淋巴细胞或T淋巴细胞对肿瘤细胞的靶向杀伤作用更强,本发明实施例的治疗癌症的治疗组合物对肿瘤细胞的靶向杀伤作用显著增强,尤其是对高表达CD19的肿瘤细胞的靶向杀伤作用显著增强。
根据本发明的实施例,上述治疗组合物还可以进一步包括下列附加技术特征至少之一:
根据本发明的实施例,所述癌症包括选自造血系统恶性肿瘤和淋巴瘤的至少之一。上述肿瘤细胞具有CD19的特异性高表达,本发明实施例的治疗组合物可使淋巴细胞细胞Nur77的沉默和高效表达抗原特异性嵌合抗原受体,如本发明实施例的CD19抗原特异性嵌合抗原受体,在肿瘤的微环境中的存活能力大大提高,所得淋巴细胞或T淋巴细胞对高表达CD19的肿瘤细胞的靶向杀伤作用更强。
附图说明
图1是根据本发明实施例的Nur77 KD慢病毒的筛选实验结果图;
图2是根据本发明实施例的T细胞转染慢病毒后的GFP和Cherry阳性率示意图;
图3是根据本发明实施例的Nur77敲低的CD19 CAR T细胞与CD19 CAR T细胞中Nur77表达水平对比试验图;
图4是根据本发明实施例的Nur77 KD CD19 CAR T与对照组体外杀伤白血病细胞对比试验图;以及
图5是根据本发明实施例的Nur77 KD CD19 CAR T细胞组与对照组体内抑制白血病细胞效果对比图。
具体实施方式
下面详细描述本发明的实施例,下面描述的实施例是示例性的,旨在用于解释本发明,而不能理解为对本发明的限制。
已有研究证实减少Nur77表达可以减少T细胞耐受。据此,我们提出一种提高CAR转化的患者T细胞持续存在并维持响应于CAR抗原的可能的解决办法,即在向T细胞转染CD19抗原同时也敲低T细胞中的Nur77的表达,减少T细胞耗竭,提高抗CD19的嵌合抗原受体T细胞对肿瘤的抑制杀伤作用。
为实现上述目的,本发明采用的技术方案是,本发明公开的一种检测抗CD19的嵌合抗原受体T细胞对白血病细胞抑制作用的方法,包括如下步骤,(1)采用PEI法制备Nur77敲低的CD19嵌合抗原受体T细胞;(2)检查Nur77敲低的CD19嵌合抗原受体T细胞(Nur77KDCD19 CAR T)中Nur77的敲除效率及这种CAR T细胞的体外扩增水平;(3)将Nur77敲低的CD19嵌合抗原受体T细胞与白血病细胞按一定比例混合检测这种CAR T细胞的体外杀伤肿瘤的作用;(4)将Nur77敲低的CD19嵌合抗原受体T细胞植入荷瘤免疫缺陷小鼠中,通过流式细胞仪检测小鼠外周血中肿瘤细胞和CAR T细胞的比例。本发明的优点在于以抗CD19的嵌合抗原受体T细胞基础,进一步敲低Nur77基因的表达,减少T细胞的耗竭,促进CAR T细胞对肿瘤的抑制和杀伤作用。制备方法简单易行,检测手段准确高效,肿瘤杀伤结果切实可靠。
本专利采用PEI法制备Nur77敲低的CD19嵌合抗原受体T细胞(Nur77 KD CD19 CART)。制备方法如下:
(1)Nur77 KD和CD19慢病毒的制备:通过293T细胞包装慢病毒,具体操作如下:①用DMEM高糖培养基加10%FBS和1%双抗培养293T细胞至100mm培养皿,待293T细胞密度达80-90%时,换成DMEM高糖培养基加1%FBS和1%双抗培养2-6h后,用PEI将pWPXLd-CAR19-EGFP或pSicoR-Nur77 KD-Cherry或对照质粒pSicoR-Me-Cherry、pMD2.G和psPAX2三个质粒转化293T细胞,每个100mm培养皿转化5μg的pWPXLd-CAR19-EGFP或对照质粒pWPXLd-EGFP,1.25μg的pMD2.G和3.75μg的psPAX2,PEI为30ug;②转化后的48h和72h收集两次次上清,上清经500g离心后,通过0.45μm过滤器过滤后分别得到Nur77 KD-Cherry,CD19-GFP和对照病毒,收集备用;
(2)T细胞的分离纯化:通过Ficoll密度梯度法分离出血液中的单个核细胞。具体方法如下:将抽取人的新鲜静脉血液按照1:1用PBS稀释后与Ficoll按照3:1的比例加入45ml离心管中,500g,4℃,离心20min.小心收集中间细胞层,得到外周血单个核细胞。
(3)T细胞的活化增殖:①预先包被抗CD3 OKT-3和CD28抗体:用PBS将抗CD3和CD28抗体稀释成1μg/ml和1μg/ml,加入48孔板中,每孔0.3ml,4℃冰箱包被8h;②T细胞用含10%FBS和1%双抗的RPMI-1640培养基稀释至5x106个/ml,将48孔板中的包被液吸掉,加入每孔1ml的含T细胞培养基,③将T细胞在37℃,5%CO2培养箱中刺激。
(4)T细胞的慢病毒转染:在T细胞刺激48h后,进行第一次感染,即小心吸除上清0.5ml,换上含8μg/ml polybrene的CD19-GFP和Nur77 KD-Cherry的慢病毒液,或者对照组加入CD19-GFP和Me-Cherry的慢病毒液。根据慢病毒滴度,MOI设为10。37℃,5%CO2培养箱培养6h后,换上新鲜的含300IU/mlIL-2的RPMI-1640培养基,37℃,5%CO2培养箱培养12h后,进行第二、三次感染。通过流式细胞仪检测GFP和Cherry呈双阳性,即说明得到了表达抗CD19且Nur77敲低的嵌合抗原受体T细胞。
进一步的,步骤(4)所制备Nur77敲低的CD19嵌合抗原受体T细胞(Nur77 KDCD19CAR T)中Nurr77的敲除效率可通过加入PMA和离子霉素(ionomycine)刺激CAR T细胞后检测细胞中Nur77的表达水平。具体如下,CAR T细胞计数后,向细胞培养液中加入PMA和离子霉素(ionomycine)在37℃,5%CO2培养箱中刺激3h,收集细胞并固定,细胞膜穿孔后,用Nur77抗体染色后,流式细胞仪检测Nur77 KD CD19 CAR T和CD19 CAR T中Nur77的表达水平。
进一步的,具有一定Nurr77的敲除效率的Nur77 KD CD19 CAR T细胞还可以在体外进行扩增:将40Gy辐照后的外周血单个核细胞与CAR T细胞按照100:1比例混合,加入含有30ng/ml OKT3 anti-CD3 antibody和3000IU/ml IL-2的RPMI-1640培养基,放入37℃,5%CO2培养箱培养。每2天进行一次半定量换液。通过该法可在5天内得到扩增100倍的CART细胞。
进一步的,可以检查Nur77 KD CD19 CAR T细胞体外肿瘤杀伤作用:这里所指的肿瘤细胞是指人急性淋巴细胞系白血病细胞株Nalm6。
进一步的,Nur77 KD CD19 CAR T细胞体外肿瘤杀伤作用具体方法如下:将Nur77KD CD19 CAR T和K19 CAR T两种CAR T细胞与Nalm6分别按照比例(21,20,2-1,2-2,2-3,2-4,2-5)混合,加入RPMI-1640培养基,放入37℃,5%CO2培养箱培养18h后,检测剩余Nalm6细胞的数量,比较两种CAR T细胞在体外肿瘤杀伤作用的差异。可见,当CAR T细胞与肿瘤细胞比例为21,20两种CAR T细胞具有较好的杀伤效果,肿瘤细胞数量减少在80%以上。当CAR T细胞与肿瘤细胞比例低于2-3时两种CAR T细胞杀伤作用出现差异,其中当肿瘤细胞杀伤为50%时K19 CAR T与肿瘤细胞比例为2-4而相同效应Nur77KD CD19 CAR T的只需要K19 CART的1/10。由此可以证明Nur77敲低的CD19 CAR T细胞在体外杀伤肿瘤细胞中比一般的CD19CAR T具有优势,尤其在肿瘤细胞多于CAR T细胞1000倍以上时,Nur77 KD CD19 CAR T的杀伤作用强于CD19 CAR T细胞。
进一步的,可以检查Nur77 KD CD19 CAR T细胞体内肿瘤杀伤作用:本专利使用的肿瘤模型动物为NOD-SCID小鼠,该种小鼠为一种免疫缺陷鼠,自身没有B、T细胞,存在NK细胞缺陷。所用的肿瘤细胞为人急性淋巴细胞系白血病细胞株Nalm6。
进一步的,Nur77 KD CD19 CAR T细胞体内肿瘤杀伤作用具体方法如下:给6周龄体重25±2g的NOD-SCID小鼠通过尾静脉注射肿瘤细胞2×106个细胞/只,并将小鼠平均分为三组技,PBS对照组,Nur77 KD CD19 CAR T治疗组和K19 CAR T治疗组,各组称重。注射肿瘤后的第二天和第三天给小鼠分别尾静脉注射Nur77 KD CD19 CAR T和K19 CAR T细胞2×106个细胞/只,对照组给予等体积PBS。小鼠肿瘤注射后每2天给各组小鼠称重,观察小鼠存活情况。
进一步的,当小鼠体重下降20%或肿瘤注射45后摘眼球取血并处死小鼠取出骨髓和脾脏,检测各组小鼠血液、脾脏和骨髓的肿瘤细胞和CAR T细胞的差异。
本发明采用上述方法获得由此可见,CD19 CAR T细胞敲低Nur77后体现出更好的体内外抑制肿瘤生长和杀死肿瘤的作用。由此可见我们制备的Nur77敲低的CD19嵌合抗原受体T细胞具有较好的生物治疗意义。
综上,本发明的有益效果:敲低抗CD19的嵌合抗原受体T细胞的Nur77有效提高抗CD19的嵌合抗原受体T细胞体内外抑制杀伤肿瘤的作用,并且Nur77敲低的抗CD19的嵌合抗原受体T细胞制备方法简单易行,质量可控,并且在体外可以进行大量扩增,能够达到临床使用数量。综上,本发明可为CAR T细胞免疫治疗提供新的思路,为CAR T临床治疗中的细胞耐受提供了新的可能性,是一种高效可控的CAR T细胞。
下面将结合实施例对本发明的方案进行解释。
本领域技术人员将会理解,下面的实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中未注明具体技术或条件的,按照本领域内的文献所描述的技术或条件(例如参考J.萨姆布鲁克等著,黄培堂等译的《分子克隆实验指南》,第三版,科学出版社)或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
实施例1 敲除Nur77的CD19 CAR T(Nur77 KD CD19 CAR T)的制备
包括如下步骤:
(1)Nur77 KD慢病毒的筛选:通过293T细胞包装慢病毒,具体操作如下:①用DMEM高糖培养基加10%FBS和1%双抗培养293T细胞至100mm培养皿,待293T细胞密度达80-90%时,换成DMEM高糖培养基加1%FBS和1%双抗培养2-6h后,用PEI将pSicoR-Nur77 KD-Cherry(Nur77 KD的shRNA序列如SEQ ID NO:3~6所示,依次命名为Nur77 KD-1,Nur77 KD-2,Nur77 KD-3,Nur77 KD-4)或对照质粒pSicoR-Me-Cherry(命名为con)三个质粒转化293T细胞,每个100mm培养皿转化5μg的pSicoR-Me-Cherry或对照质粒pSicoR-Me-Cherry,1.25μg的pMD2.G和3.75μg的psPAX2,PEI为30ug;②转化后的48h和72h收集两次次上清,上清经500g离心后,通过0.45μm过滤器过滤后分别得到Nur77 KD-Cherry和对照病毒,收集去转染T细胞,发现SEQ ID NO:3所示的Nur77KD(Nur77 KD-1)的shRNA在沉默靶基因Nur77上效果最优,结果如图1所示);
(2)Nur77 KD和CD19慢病毒的制备:通过293T细胞包装慢病毒,具体操作如下:①用DMEM高糖培养基加10%FBS和1%双抗培养293T细胞至100mm培养皿,待293T细胞密度达80-90%时,换成DMEM高糖培养基加1%FBS和1%双抗培养2-6h后,用PEI将pWPXLd-CAR19-EGFP或pSicoR-Nur77 KD-Cherry(Nur77 KD的shRNA序列如SEQ ID NO:3所示)或对照质粒pSicoR-Me-Cherry、pMD2.G和psPAX2三个质粒转化293T细胞,每个100mm培养皿转化5μg的pWPXLd-CAR19-EGFP或对照质粒pWPXLd-EGFP,1.25μg的pMD2.G和3.75μg的psPAX2,PEI为30ug;②转化后的48h和72h收集两次次上清,上清经500g离心后,通过0.45μm过滤器过滤后分别得到Nur77 KD-Cherry,CD19-GFP和对照病毒,收集备用;
(3)T细胞的分离纯化:通过Ficoll密度梯度法分离出血液中的单个核细胞。具体方法如下:将抽取人的新鲜静脉血液按照1:1用PBS稀释后与Ficoll按照3:1的比例加入45ml离心管中,500g,4℃,离心20min.小心收集中间细胞层,得到外周血单个核细胞。
(4)T细胞的活化增殖:①预先包被抗CD3 OKT-3和CD28抗体:用PBS将抗CD3和CD28抗体稀释成1μg/ml和1μg/ml,加入48孔板中,每孔0.3ml,4℃冰箱包被8h;②T细胞用含10%FBS和1%双抗的RPMI-1640培养基稀释至5x106个/ml,将48孔板中的包被液吸掉,加入每孔1ml的含T细胞培养基,③将T细胞在37℃,5%CO2培养箱中刺激。
(5)T细胞的慢病毒转染:在T细胞刺激48h后,进行第一次感染,即小心吸除上清0.5ml,换上含8μg/ml polybrene的CD19-GFP和Nur77 KD-Cherry的慢病毒液,或者对照组加入CD19-GFP和Me-Cherry的慢病毒液。根据慢病毒滴度,MOI设为10。37℃,5%CO2培养箱培养6h后,换上新鲜的含300IU/mlIL-2的RPMI-1640培养基,37℃,5%CO2培养箱培养12h后,进行第二、三次感染。最后,通过流式细胞仪检测GFP和Cherry双阳性表示该T细胞仅能够表达CD19抗原的同时又有Nur77的敲低,见图2,Nur77 KD CD19 CAR T细胞占有比例为71.1%。
进一步的,步骤(5)所制备Nur77敲低的CD19嵌合抗原受体T细胞(Nur77 KDCD19CAR T)中Nurr77的敲除效率可通过加入PMA和离子霉素(ionomycine)刺激CAR T细胞后检测细胞中Nur77的表达水平。具体如下,CAR T细胞计数后,向细胞培养液中加入PMA和离子霉素(ionomycine)在37℃,5%CO2培养箱中刺激3h,收集细胞并固定,细胞膜穿孔后,用Nur77抗体染色后,流式细胞仪检测Nur77 KD CD19 CAR T和CD19 CAR T中Nur77的表达水平。由图3可知,Nur77的敲除效率可以达到29.2%。
进一步的,具有一定Nurr77的敲除效率的Nur77 KD CD19 CAR T细胞还可以在体外进行扩增:将40Gy辐照后的外周血单个核细胞与CAR T细胞按照100:1比例混合,加入含有30ng/ml OKT3 anti-CD3 antibody和3000IU/ml IL-2的RPMI-1640培养基,放入37℃,5%CO2培养箱培养。每2天进行一次半定量换液。通过该法可在5天内得到扩增100倍的CART细胞。
实施例2 Nur77敲低的抗CD19 CAR T细胞体外肿瘤杀伤
本实施例以人急性淋巴细胞系白血病细胞株Nalm6为例。具体步骤如下:
将Nur77 KD CD19 CAR T和CD19 CAR T两种CAR T细胞与Nalm6分别按照比例(21,20,2-1,2-2,2-3,2-4,2-5)混合,加入RPMI-1640培养基,放入37℃,5%CO2培养箱培养18h后,检测剩余Nalm6细胞的数量,比较两种CAR T细胞在体外肿瘤杀伤作用的差异。图4可见,当CART细胞与肿瘤细胞比例为21,20两种CAR T细胞具有较好的杀伤效果,肿瘤细胞数量减少在80%以上。当肿瘤细胞杀伤为50%时CD19 CAR T与肿瘤细胞比例为2-1而相同效应Nur77KD CD19 CAR T的只需要CD19 CAR T的1/10。由此可以证明Nur77敲低的CD19 CAR T细胞在体外杀伤肿瘤细胞中比一般的CD19 CAR T具有优势,尤其在肿瘤细胞多于CAR T细胞100倍以上时,Nur77 KD CD19 CAR T的杀伤作用强于CD19CAR T细胞。
实施例3 Nur77敲低的抗CD19 CAR T细胞体内肿瘤杀伤
本实施例以人急性淋巴细胞系白血病细胞株Nalm6为例。使用的肿瘤模型动物为NOD-SCID小鼠,该种小鼠为一种免疫缺陷鼠,自身没有B、T细胞,存在NK细胞缺陷。具体实施步骤如下,给6周龄体重25±2g的NOD-SCID小鼠通过尾静脉注射肿瘤细胞2×106个细胞/只,并将小鼠平均分为三组技,PBS对照组,Nur77 KD CD19 CAR T治疗组和CD19 CAR T治疗组,各组称重。注射肿瘤后的第二天和第三天给小鼠分别尾静脉注射Nur77 KD CD19 CAR T和CD19 CAR T细胞2×106个细胞/只,对照组给予等体积PBS。小鼠肿瘤注射后每2天给各组小鼠称重,观察小鼠存活情况。当小鼠体重下降20%或肿瘤注射45后摘眼球取血并处死小鼠取出骨髓和脾脏,检测各组小鼠血液、脾脏和骨髓的肿瘤细胞和CAR T细胞的差异。
本发明采用上述方法获得由此可见,CD19 CAR T细胞在敲低Nur77后体现出更好的体内外抑制肿瘤生长和杀死肿瘤的作用。结果如图5所示。由此可见我们制备的Nur77敲低后的CD19嵌合抗原受体T细胞具有较好的生物治疗意义。
在本说明书的描述中,参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不必须针对的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任一个或多个实施例或示例中以合适的方式结合。此外,在不相互矛盾的情况下,本领域的技术人员可以将本说明书中描述的不同实施例或示例以及不同实施例或示例的特征进行结合和组合。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
SEQUENCE LISTING
<110> 浙江帝格生物科技有限责任公司
<120> 共表达抗CD19嵌合抗原受体和Nur77抑制分子的转基因淋巴细胞及其用途
<130> PIDC3195870
<160> 8
<170> PatentIn version 3.5
<210> 1
<211> 489
<212> PRT
<213> Artificial Sequence
<220>
<223> 嵌合抗原受体的氨基酸序列
<400> 1
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser
20 25 30
Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser
35 40 45
Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly
50 55 60
Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val
65 70 75 80
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr
85 90 95
Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln
100 105 110
Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
115 120 125
Thr Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser
130 135 140
Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala
145 150 155 160
Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu
165 170 175
Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu
180 185 190
Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser
195 200 205
Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln
210 215 220
Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr
225 230 235 240
Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr
245 250 255
Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ala Ala Ile Glu
260 265 270
Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr
275 280 285
Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro
290 295 300
Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu
305 310 315 320
Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
325 330 335
Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
340 345 350
Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
355 360 365
Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser
370 375 380
Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
385 390 395 400
Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
405 410 415
Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
420 425 430
Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
435 440 445
Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
450 455 460
Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
465 470 475 480
Leu His Met Gln Ala Leu Pro Pro Arg
485
<210> 2
<211> 1467
<212> DNA
<213> Artificial Sequence
<220>
<223> 编码嵌合抗原受体的核酸分子的核苷酸序列
<400> 2
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg 60
atcccagaca tccagatgac acagactaca tcctccctgt ctgcctctct gggagacaga 120
gtcaccatca gttgcagggc aagtcaggac attagtaaat atttaaattg gtatcagcag 180
aaaccagatg gaactgttaa actcctgatc taccatacat caagattaca ctcaggagtc 240
ccatcaaggt tcagtggcag tgggtctgga acagattatt ctctcaccat tagcaacctg 300
gagcaagaag atattgccac ttacttttgc caacagggta atacgcttcc gtacacgttc 360
ggagggggga ctaagttgga aataacaggc tccacctctg gatccggcaa gcccggatct 420
ggcgagggat ccaccaaggg cgaggtgaaa ctgcaggagt caggacctgg cctggtggcg 480
ccctcacaga gcctgtccgt cacatgcact gtctcagggg tctcattacc cgactatggt 540
gtaagctgga ttcgccagcc tccacgaaag ggtctggagt ggctgggagt aatatggggt 600
agtgaaacca catactataa ttcagctctc aaatccagac tgaccatcat caaggacaac 660
tccaagagcc aagttttctt aaaaatgaac agtctgcaaa ctgatgacac agccatttac 720
tactgtgcca aacattatta ctacggtggt agctatgcta tggactactg gggtcaagga 780
acctcagtca ccgtctcctc agcggccgca attgaagtta tgtatcctcc tccttaccta 840
gacaatgaga agagcaatgg aaccattatc catgtgaaag ggaaacacct ttgtccaagt 900
cccctatttc ccggaccttc taagcccttt tgggtgctgg tggtggttgg gggagtcctg 960
gcttgctata gcttgctagt aacagtggcc tttattattt tctgggtgag gagtaagagg 1020
agcaggctcc tgcacagtga ctacatgaac atgactcccc gccgccccgg gcccacccgc 1080
aagcattacc agccctatgc cccaccacgc gacttcgcag cctatcgctc cagagtgaag 1140
ttcagcagga gcgcagacgc ccccgcgtac cagcagggcc agaaccagct ctataacgag 1200
ctcaatctag gacgaagaga ggagtacgat gttttggaca agagacgtgg ccgggaccct 1260
gagatggggg gaaagccgag aaggaagaac cctcaggaag gcctgtacaa tgaactgcag 1320
aaagataaga tggcggaggc ctacagtgag attgggatga aaggcgagcg ccggaggggc 1380
aaggggcacg atggccttta ccagggtctc agtacagcca ccaaggacac ctacgacgcc 1440
cttcacatgc aggccctgcc ccctcgc 1467
<210> 3
<211> 58
<212> DNA
<213> Artificial Sequence
<220>
<223> 沉默Nur77的核酸分子的核苷酸序列
<400> 3
cccggctcct tcaagttcga ggacttgaat tcaagtcctc gaacttgaag gagttttt 58
<210> 4
<211> 58
<212> DNA
<213> Artificial Sequence
<220>
<223> 沉默Nur77的核酸分子的核苷酸序列
<400> 4
cccgggattg acagtatcct ggccttgaat tcaaggccag gatactgtca atcttttt 58
<210> 5
<211> 58
<212> DNA
<213> Artificial Sequence
<220>
<223> 沉默Nur77的核酸分子的核苷酸序列
<400> 5
cccggtggtg aaggaagttg tccgaagaat tcttcggaca acttccttca ccattttt 58
<210> 6
<211> 58
<212> DNA
<213> Artificial Sequence
<220>
<223> 沉默Nur77的核酸分子的核苷酸序列
<400> 6
cccgggctac acaggagagt ttgacagaat tctgtcaaac tctcctgtgt agcttttt 58
<210> 7
<211> 11903
<212> DNA
<213> Artificial Sequence
<220>
<223> 表达CD19 CAR的核酸的核苷酸序列
<400> 7
ttggaagggc taattcactc ccaaagaaga caagatatcc ttgatctgtg gatctaccac 60
acacaaggct acttccctga ttagcagaac tacacaccag ggccaggggt cagatatcca 120
ctgacctttg gatggtgcta caagctagta ccagttgagc cagataaggt agaagaggcc 180
aataaaggag agaacaccag cttgttacac cctgtgagcc tgcatgggat ggatgacccg 240
gagagagaag tgttagagtg gaggtttgac agccgcctag catttcatca cgtggcccga 300
gagctgcatc cggagtactt caagaactgc tgatatcgag cttgctacaa gggactttcc 360
gctggggact ttccagggag gcgtggcctg ggcgggactg gggagtggcg agccctcaga 420
tcctgcatat aagcagctgc tttttgcctg tactgggtct ctctggttag accagatctg 480
agcctgggag ctctctggct aactagggaa cccactgctt aagcctcaat aaagcttgcc 540
ttgagtgctt caagtagtgt gtgcccgtct gttgtgtgac tctggtaact agagatccct 600
cagacccttt tagtcagtgt ggaaaatctc tagcagtggc gcccgaacag ggacttgaaa 660
gcgaaaggga aaccagagga gctctctcga cgcaggactc ggcttgctga agcgcgcacg 720
gcaagaggcg aggggcggcg actggtgagt acgccaaaaa ttttgactag cggaggctag 780
aaggagagag atgggtgcga gagcgtcagt attaagcggg ggagaattag atcgcgatgg 840
gaaaaaattc ggttaaggcc agggggaaag aaaaaatata aattaaaaca tatagtatgg 900
gcaagcaggg agctagaacg attcgcagtt aatcctggcc tgttagaaac atcagaaggc 960
tgtagacaaa tactgggaca gctacaacca tcccttcaga caggatcaga agaacttaga 1020
tcattatata atacagtagc aaccctctat tgtgtgcatc aaaggataga gataaaagac 1080
accaaggaag ctttagacaa gatagaggaa gagcaaaaca aaagtaagac caccgcacag 1140
caagcggccg ctgatcttca gacctggagg aggagatatg agggacaatt ggagaagtga 1200
attatataaa tataaagtag taaaaattga accattagga gtagcaccca ccaaggcaaa 1260
gagaagagtg gtgcagagag aaaaaagagc agtgggaata ggagctttgt tccttgggtt 1320
cttgggagca gcaggaagca ctatgggcgc agcgtcaatg acgctgacgg tacaggccag 1380
acaattattg tctggtatag tgcagcagca gaacaatttg ctgagggcta ttgaggcgca 1440
acagcatctg ttgcaactca cagtctgggg catcaagcag ctccaggcaa gaatcctggc 1500
tgtggaaaga tacctaaagg atcaacagct cctggggatt tggggttgct ctggaaaact 1560
catttgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc tggaacagat 1620
ttggaatcac acgacctgga tggagtggga cagagaaatt aacaattaca caagcttaat 1680
acactcctta attgaagaat cgcaaaacca gcaagaaaag aatgaacaag aattattgga 1740
attagataaa tgggcaagtt tgtggaattg gtttaacata acaaattggc tgtggtatat 1800
aaaattattc ataatgatag taggaggctt ggtaggttta agaatagttt ttgctgtact 1860
ttctatagtg aatagagtta ggcagggata ttcaccatta tcgtttcaga cccacctccc 1920
aaccccgagg ggacccgaca ggcccgaagg aatagaagaa gaaggtggag agagagacag 1980
agacagatcc attcgattag tgaacggatc tcgacggtat cgatgtcgac gataagcttt 2040
gcaaagatgg ataaagtttt aaacagagag gaatctttgc agctaatgga ccttctaggt 2100
cttgaaagga gtgggaattg gctccggtgc ccgtcagtgg gcagagcgca catcgcccac 2160
agtccccgag aagttggggg gaggggtcgg caattgaacc ggtgcctaga gaaggtggcg 2220
cggggtaaac tgggaaagtg atgtcgtgta ctggctccgc ctttttcccg agggtggggg 2280
agaaccgtat ataagtgcag tagtcgccgt gaacgttctt tttcgcaacg ggtttgccgc 2340
cagaacacag gtaagtgccg tgtgtggttc ccgcgggcct ggcctcttta cgggttatgg 2400
cccttgcgtg ccttgaatta cttccactgg ctgcagtacg tgattcttga tcccgagctt 2460
cgggttggaa gtgggtggga gagttcgagg ccttgcgctt aaggagcccc ttcgcctcgt 2520
gcttgagttg aggcctggcc tgggcgctgg ggccgccgcg tgcgaatctg gtggcacctt 2580
cgcgcctgtc tcgctgcttt cgataagtct ctagccattt aaaatttttg atgacctgct 2640
gcgacgcttt ttttctggca agatagtctt gtaaatgcgg gccaagatct gcacactggt 2700
atttcggttt ttggggccgc gggcggcgac ggggcccgtg cgtcccagcg cacatgttcg 2760
gcgaggcggg gcctgcgagc gcggccaccg agaatcggac gggggtagtc tcaagctggc 2820
cggcctgctc tggtgcctgg cctcgcgccg ccgtgtatcg ccccgccctg ggcggcaagg 2880
ctggcccggt cggcaccagt tgcgtgagcg gaaagatggc cgcttcccgg ccctgctgca 2940
gggagctcaa aatggaggac gcggcgctcg ggagagcggg cgggtgagtc acccacacaa 3000
aggaaaaggg cctttccgtc ctcagccgtc gcttcatgtg actccacgga gtaccgggcg 3060
ccgtccaggc acctcgatta gttctcgagc ttttggagta cgtcgtcttt aggttggggg 3120
gaggggtttt atgcgatgga gtttccccac actgagtggg tggagactga agttaggcca 3180
gcttggcact tgatgtaatt ctccttggaa tttgcccttt ttgagtttgg atcttggttc 3240
attctcaagc ctcagacagt ggttcaaagt ttttttcttc catttcaggt gtcgtgagga 3300
atttcgacat ttaaatttaa ttaatctcga cggtatcggt taacttttaa aagaaaaggg 3360
gggattgggg ggtacagtgc aggggaaaga atagtagaca taatagcaac agacatacaa 3420
actaaagaat tacaaaaaca aattacaaaa attcaaaatt ttccgatcac gagactagcc 3480
tcgaggttta aacgaattca tgcttctcct ggtgacaagc cttctgctct gtgagttacc 3540
acacccagca ttcctcctga tcccagacat ccagatgaca cagactacat cctccctgtc 3600
tgcctctctg ggagacagag tcaccatcag ttgcagggca agtcaggaca ttagtaaata 3660
tttaaattgg tatcagcaga aaccagatgg aactgttaaa ctcctgatct accatacatc 3720
aagattacac tcaggagtcc catcaaggtt cagtggcagt gggtctggaa cagattattc 3780
tctcaccatt agcaacctgg agcaagaaga tattgccact tacttttgcc aacagggtaa 3840
tacgcttccg tacacgttcg gaggggggac taagttggaa ataacaggct ccacctctgg 3900
atccggcaag cccggatctg gcgagggatc caccaagggc gaggtgaaac tgcaggagtc 3960
aggacctggc ctggtggcgc cctcacagag cctgtccgtc acatgcactg tctcaggggt 4020
ctcattaccc gactatggtg taagctggat tcgccagcct ccacgaaagg gtctggagtg 4080
gctgggagta atatggggta gtgaaaccac atactataat tcagctctca aatccagact 4140
gaccatcatc aaggacaact ccaagagcca agttttctta aaaatgaaca gtctgcaaac 4200
tgatgacaca gccatttact actgtgccaa acattattac tacggtggta gctatgctat 4260
ggactactgg ggtcaaggaa cctcagtcac cgtctcctca gcggccgcaa ttgaagttat 4320
gtatcctcct ccttacctag acaatgagaa gagcaatgga accattatcc atgtgaaagg 4380
gaaacacctt tgtccaagtc ccctatttcc cggaccttct aagccctttt gggtgctggt 4440
ggtggttggg ggagtcctgg cttgctatag cttgctagta acagtggcct ttattatttt 4500
ctgggtgagg agtaagagga gcaggctcct gcacagtgac tacatgaaca tgactccccg 4560
ccgccccggg cccacccgca agcattacca gccctatgcc ccaccacgcg acttcgcagc 4620
ctatcgctcc agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca 4680
gaaccagctc tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa 4740
gagacgtggc cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg 4800
cctgtacaat gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa 4860
aggcgagcgc cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac 4920
caaggacacc tacgacgccc ttcacatgca ggccctgccc cctcgcacta gtaaaattgt 4980
cgctcctgtc aaacaaactc ttaactttga tttactcaaa ctggctgggg atgtagaaag 5040
caatccaggt ccagctagca tggtgagcaa gggcgaggag ctgttcaccg gggtggtgcc 5100
catcctggtc gagctggacg gcgacgtaaa cggccacaag ttcagcgtgt ccggcgaggg 5160
cgagggcgat gccacctacg gcaagctgac cctgaagttc atctgcacca ccggcaagct 5220
gcccgtgccc tggcccaccc tcgtgaccac cctgacctac ggcgtgcagt gcttcagccg 5280
ctaccccgac cacatgaagc agcacgactt cttcaagtcc gccatgcccg aaggctacgt 5340
ccaggagcgc accatcttct tcaaggacga cggcaactac aagacccgcg ccgaggtgaa 5400
gttcgagggc gacaccctgg tgaaccgcat cgagctgaag ggcatcgact tcaaggagga 5460
cggcaacatc ctggggcaca agctggagta caactacaac agccacaacg tctatatcat 5520
ggccgacaag cagaagaacg gcatcaaggt gaacttcaag atccgccaca acatcgagga 5580
cggcagcgtg cagctcgccg accactacca gcagaacacc cccatcggcg acggccccgt 5640
gctgctgccc gacaaccact acctgagcac ccagtccgcc ctgagcaaag accccaacga 5700
gaagcgcgat cacatggtcc tgctggagtt cgtgaccgcc gccgggatca ctctcggcat 5760
ggacgagctg tacaagtaac atatgataat caacctctgg attacaaaat ttgtgaaaga 5820
ttgactggta ttcttaacta tgttgctcct tttacgctat gtggatacgc tgctttaatg 5880
cctttgtatc atgctattgc ttcccgtatg gctttcattt tctcctcctt gtataaatcc 5940
tggttgctgt ctctttatga ggagttgtgg cccgttgtca ggcaacgtgg cgtggtgtgc 6000
actgtgtttg ctgacgcaac ccccactggt tggggcattg ccaccacctg tcagctcctt 6060
tccgggactt tcgctttccc cctccctatt gccacggcgg aactcatcgc cgcctgcctt 6120
gcccgctgct ggacaggggc tcggctgttg ggcactgaca attccgtggt gttgtcgggg 6180
aagctgacgt cctttccatg gctgctcgcc tgtgttgcca cctggattct gcgcgggacg 6240
tccttctgct acgtcccttc ggccctcaat ccagcggacc ttccttcccg cggcctgctg 6300
ccggctctgc ggcctcttcc gcgtcttcgc cttcgccctc agacgagtcg gatctccctt 6360
tgggccgcct ccccgcatcg gtacgtatgg ccaggtacct ttaagaccaa tgacttacaa 6420
ggcagctgta gatcttagcc actttttaaa agaaaagggg ggactggaag ggctaattca 6480
ctcccaacga agacaagatc tgctttttgc ttgtactggg tctctctggt tagaccagat 6540
ctgagcctgg gagctctctg gctaactagg gaacccactg cttaagcctc aataaagctt 6600
gccttgagtg cttcaagtag tgtgtgcccg tctgttgtgt gactctggta actagagatc 6660
cctcagaccc ttttagtcag tgtggaaaat ctctagcagc atctagaatt aattccgtgt 6720
attctatagt gtcacctaaa tcgtatgtgt atgatacata aggttatgta ttaattgtag 6780
ccgcgttcta acgacaatat gtacaagcct aattgtgtag catctggctt actgaagcag 6840
accctatcat ctctctcgta aactgccgtc agagtcggtt tggttggacg aaccttctga 6900
gtttctggta acgccgtccc gcacccggaa atggtcagcg aaccaatcag cagggtcatc 6960
gctagccaga tcctctacgc cggacgcatc gtggccggca tcaccggcgc cacaggtgcg 7020
gttgctggcg cctatatcgc cgacatcacc gatggggaag atcgggctcg ccacttcggg 7080
ctcatgagcg cttgtttcgg cgtgggtatg gtggcaggcc ccgtggccgg gggactgttg 7140
ggcgccatct ccttgcatgc accattcctt gcggcggcgg tgctcaacgg cctcaaccta 7200
ctactgggct gcttcctaat gcaggagtcg cataagggag agcgtcgaat ggtgcactct 7260
cagtacaatc tgctctgatg ccgcatagtt aagccagccc cgacacccgc caacacccgc 7320
tgacgcgccc tgacgggctt gtctgctccc ggcatccgct tacagacaag ctgtgaccgt 7380
ctccgggagc tgcatgtgtc agaggttttc accgtcatca ccgaaacgcg cgagacgaaa 7440
gggcctcgtg atacgcctat ttttataggt taatgtcatg ataataatgg tttcttagac 7500
gtcaggtggc acttttcggg gaaatgtgcg cggaacccct atttgtttat ttttctaaat 7560
acattcaaat atgtatccgc tcatgagaca ataaccctga taaatgcttc aataatattg 7620
aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc cttattccct tttttgcggc 7680
attttgcctt cctgtttttg ctcacccaga aacgctggtg aaagtaaaag atgctgaaga 7740
tcagttgggt gcacgagtgg gttacatcga actggatctc aacagcggta agatccttga 7800
gagttttcgc cccgaagaac gttttccaat gatgagcact tttaaagttc tgctatgtgg 7860
cgcggtatta tcccgtattg acgccgggca agagcaactc ggtcgccgca tacactattc 7920
tcagaatgac ttggttgagt actcaccagt cacagaaaag catcttacgg atggcatgac 7980
agtaagagaa ttatgcagtg ctgccataac catgagtgat aacactgcgg ccaacttact 8040
tctgacaacg atcggaggac cgaaggagct aaccgctttt ttgcacaaca tgggggatca 8100
tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa gccataccaa acgacgagcg 8160
tgacaccacg atgcctgtag caatggcaac aacgttgcgc aaactattaa ctggcgaact 8220
acttactcta gcttcccggc aacaattaat agactggatg gaggcggata aagttgcagg 8280
accacttctg cgctcggccc ttccggctgg ctggtttatt gctgataaat ctggagccgg 8340
tgagcgtggg tctcgcggta tcattgcagc actggggcca gatggtaagc cctcccgtat 8400
cgtagttatc tacacgacgg ggagtcaggc aactatggat gaacgaaata gacagatcgc 8460
tgagataggt gcctcactga ttaagcattg gtaactgtca gaccaagttt actcatatat 8520
actttagatt gatttaaaac ttcattttta atttaaaagg atctaggtga agatcctttt 8580
tgataatctc atgaccaaaa tcccttaacg tgagttttcg ttccactgag cgtcagaccc 8640
cgtagaaaag atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt 8700
gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg ccggatcaag agctaccaac 8760
tctttttccg aaggtaactg gcttcagcag agcgcagata ccaaatactg tccttctagt 8820
gtagccgtag ttaggccacc acttcaagaa ctctgtagca ccgcctacat acctcgctct 8880
gctaatcctg ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttgga 8940
ctcaagacga tagttaccgg ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac 9000
acagcccagc ttggagcgaa cgacctacac cgaactgaga tacctacagc gtgagcattg 9060
agaaagcgcc acgcttcccg aagggagaaa ggcggacagg tatccggtaa gcggcagggt 9120
cggaacagga gagcgcacga gggagcttcc agggggaaac gcctggtatc tttatagtcc 9180
tgtcgggttt cgccacctct gacttgagcg tcgatttttg tgatgctcgt caggggggcg 9240
gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct tttgctggcc 9300
ttttgctcac atgttctttc ctgcgttatc ccctgattct gtggataacc gtattaccgc 9360
ctttgagtga gctgataccg ctcgccgcag ccgaacgacc gagcgcagcg agtcagtgag 9420
cgaggaagcg gaagagcgcc caatacgcaa accgcctctc cccgcgcgtt ggccgattca 9480
ttaatgcagc tgtggaatgt gtgtcagtta gggtgtggaa agtccccagg ctccccagca 9540
ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa ccaggtgtgg aaagtcccca 9600
ggctccccag caggcagaag tatgcaaagc atgcatctca attagtcagc aaccatagtc 9660
ccgcccctaa ctccgcccat cccgccccta actccgccca gttccgccca ttctccgccc 9720
catggctgac taattttttt tatttatgca gaggccgagg ccgcctcggc ctctgagcta 9780
ttccagaagt agtgaggagg cttttttgga ggcctaggct tttgcaaaaa gcttggacac 9840
aagacaggct tgcgagatat gtttgagaat accactttat cccgcgtcag ggagaggcag 9900
tgcgtaaaaa gacgcggact catgtgaaat actggttttt agtgcgccag atctctataa 9960
tctcgcgcaa cctattttcc cctcgaacac tttttaagcc gtagataaac aggctgggac 10020
acttcacatg agcgaaaaat acatcgtcac ctgggacatg ttgcagatcc atgcacgtaa 10080
actcgcaagc cgactgatgc cttctgaaca atggaaaggc attattgccg taagccgtgg 10140
cggtctgtac cgggtgcgtt actggcgcgt gaactgggta ttcgtcatgt cgataccgtt 10200
tgtatttcca gctacgatca cgacaaccag cgcgagctta aagtgctgaa acgcgcagaa 10260
ggcgatggcg aaggcttcat cgttattgat gacctggtgg ataccggtgg tactgcggtt 10320
gcgattcgtg aaatgtatcc aaaagcgcac tttgtcacca tcttcgcaaa accggctggt 10380
cgtccgctgg ttgatgacta tgttgttgat atcccgcaag atacctggat tgaacagccg 10440
tgggatatgg gcgtcgtatt cgtcccgcca atctccggtc gctaatcttt tcaacgcctg 10500
gcactgccgg gcgttgttct ttttaacttc aggcgggtta caatagtttc cagtaagtat 10560
tctggaggct gcatccatga cacaggcaaa cctgagcgaa accctgttca aaccccgctt 10620
taaacatcct gaaacctcga cgctagtccg ccgctttaat cacggcgcac aaccgcctgt 10680
gcagtcggcc cttgatggta aaaccatccc tcactggtat cgcatgatta accgtctgat 10740
gtggatctgg cgcggcattg acccacgcga aatcctcgac gtccaggcac gtattgtgat 10800
gagcgatgcc gaacgtaccg acgatgattt atacgatacg gtgattggct accgtggcgg 10860
caactggatt tatgagtggg ccccggatct ttgtgaagga accttacttc tgtggtgtga 10920
cataattgga caaactacct acagagattt aaagctctaa ggtaaatata aaatttttaa 10980
gtgtataatg tgttaaacta ctgattctaa ttgtttgtgt attttagatt ccaacctatg 11040
gaactgatga atgggagcag tggtggaatg cctttaatga ggaaaacctg ttttgctcag 11100
aagaaatgcc atctagtgat gatgaggcta ctgctgactc tcaacattct actcctccaa 11160
aaaagaagag aaaggtagaa gaccccaagg actttccttc agaattgcta agttttttga 11220
gtcatgctgt gtttagtaat agaactcttg cttgctttgc tatttacacc acaaaggaaa 11280
aagctgcact gctatacaag aaaattatgg aaaaatattc tgtaaccttt ataagtaggc 11340
ataacagtta taatcataac atactgtttt ttcttactcc acacaggcat agagtgtctg 11400
ctattaataa ctatgctcaa aaattgtgta cctttagctt tttaatttgt aaaggggtta 11460
ataaggaata tttgatgtat agtgccttga ctagagatca taatcagcca taccacattt 11520
gtagaggttt tacttgcttt aaaaaacctc ccacacctcc ccctgaacct gaaacataaa 11580
atgaatgcaa ttgttgttgt taacttgttt attgcagctt ataatggtta caaataaagc 11640
aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag ttgtggtttg 11700
tccaaactca tcaatgtatc ttatcatgtc tggatcaact ggataactca agctaaccaa 11760
aatcatccca aacttcccac cccataccct attaccactg ccaattacct agtggtttca 11820
tttactctaa acctgtgatt cctctgaatt attttcattt taaagaaatt gtatttgtta 11880
aatatgtact acaaacttag tag 11903
<210> 8
<211> 7593
<212> DNA
<213> Artificial Sequence
<220>
<223> 沉默Nur77的核酸的核苷酸序列
<400> 8
gacattgatt attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc 60
catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgccca 120
acgacccccg cccattgacg tcaataatga cgtatgttcc catagtaacg ccaataggga 180
ctttccattg acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc 240
aagtgtatca tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct 300
ggcattatgc ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat 360
tagtcatcgc tattaccatg gtgatgcggt tttggcagta catcaatggg cgtggatagc 420
ggtttgactc acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt 480
ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa ctccgcccca ttgacgcaaa 540
tgggcggtag gcgtgtacgg tgggaggtct atataagcag cgcgttttgc ctgtactggg 600
tctctctggt tagaccagat ctgagcctgg gagctctctg gctaactagg gaacccactg 660
cttaagcctc aataaagctt gccttgagtg cttcaagtag tgtgtgcccg tctgttgtgt 720
gactctggta actagagatc cctcagaccc ttttagtcag tgtggaaaat ctctagcagt 780
ggcgcccgaa cagggacttg aaagcgaaag ggaaaccaga ggagctctct cgacgcagga 840
ctcggcttgc tgaagcgcgc acggcaagag gcgaggggcg gcgactggtg agtacgccaa 900
aaattttgac tagcggaggc tagaaggaga gagatgggtg cgagagcgtc agtattaagc 960
gggggagaat tagatcgcga tgggaaaaaa ttcggttaag gccaggggga aagaaaaaat 1020
ataaattaaa acatatagta tgggcaagca gggagctaga acgattcgca gttaatcctg 1080
gcctgttaga aacatcagaa ggctgtagac aaatactggg acagctacaa ccatcccttc 1140
agacaggatc agaagaactt agatcattat ataatacagt agcaaccctc tattgtgtgc 1200
atcaaaggat agagataaaa gacaccaagg aagctttaga caagatagag gaagagcaaa 1260
acaaaagtaa gaccaccgca cagcaagcgg ccggccgctg atcttcagac ctggaggagg 1320
agatatgagg gacaattgga gaagtgaatt atataaatat aaagtagtaa aaattgaacc 1380
attaggagta gcacccacca aggcaaagag aagagtggtg cagagagaaa aaagagcagt 1440
gggaatagga gctttgttcc ttgggttctt gggagcagca ggaagcacta tgggcgcagc 1500
gtcaatgacg ctgacggtac aggccagaca attattgtct ggtatagtgc agcagcagaa 1560
caatttgctg agggctattg aggcgcaaca gcatctgttg caactcacag tctggggcat 1620
caagcagctc caggcaagaa tcctggctgt ggaaagatac ctaaaggatc aacagctcct 1680
ggggatttgg ggttgctctg gaaaactcat ttgcaccact gctgtgcctt ggaatgctag 1740
ttggagtaat aaatctctgg aacagatttg gaatcacacg acctggatgg agtgggacag 1800
agaaattaac aattacacaa gcttaataca ctccttaatt gaagaatcgc aaaaccagca 1860
agaaaagaat gaacaagaat tattggaatt agataaatgg gcaagtttgt ggaattggtt 1920
taacataaca aattggctgt ggtatataaa attattcata atgatagtag gaggcttggt 1980
aggtttaaga atagtttttg ctgtactttc tatagtgaat agagttaggc agggatattc 2040
accattatcg tttcagaccc acctcccaac cccgagggga cccgacaggc ccgaaggaat 2100
agaagaagaa ggtggagaga gagacagaga cagatccatt cgattagtga acggatcggc 2160
actgcgtgcg ccaattctgc agacaaatgg cagtattcat ccacaatttt aaaagaaaag 2220
gggggattgg ggggtacagt gcaggggaaa gaatagtaga cataatagca acagacatac 2280
aaactaaaga attacaaaaa caaattacaa aaattcaaaa ttttcgggtt tattacaggg 2340
acagcagaga tccagtttgg ttagtaccgg gcccgctcta gagatccgac gcgccatctc 2400
taggcccgcg ccggccccct cgcacagact tgtgggagaa gctcggctac tcccctgccc 2460
cggttaattt gcatataata tttcctagta actatagagg cttaatgtgc gataaaagac 2520
agataatctg ttctttttaa tactagctac attttacatg ataggcttgg atttctataa 2580
cttcgtatag catacattat acgaagttat acatgtcaca aaaggaaact caccctaact 2640
gtaaagtaat tgtgtgtttt gagactataa atatcccttg gagaaaagcc ttgttaaccc 2700
cggctccttc aagttcgagg acttgaattc aagtcctcga acttgaagga gtttttctcg 2760
agtactagga tccattaggc ggccgcgtgg ataaccgtat taccgccatg cattagttat 2820
taatagtaat caattacggg gtcattagtt catagcccat atatggagtt ccgcgttaca 2880
taacttacgg taaatggccc gcctggctga ccgcccaacg acccccgccc attgacgtca 2940
ataatgacgt atgttcccat agtaacgcca atagggactt tccattgacg tcaatgggtg 3000
gagtatttac ggtaaactgc ccacttggca gtacatcaag tgtatcatat gccaagtacg 3060
ccccctattg acgtcaatga cggtaaatgg cccgcctggc attatgccca gtacatgacc 3120
ttatgggact ttcctacttg gcagtacatc tacgtattag tcatcgctat taccatggtg 3180
atgcggtttt ggcagtacat caatgggcgt ggatagcggt ttgactcacg gggatttcca 3240
agtctccacc ccattgacgt caatgggagt ttgttttggc accaaaatca acgggacttt 3300
ccaaaatgtc gtaacaactc cgccccattg acgcaaatgg gcggtaggcg tgtacggtgg 3360
gaggtctata taagcagagc tggtttagtg aaccgtcaga tccgctagcg ctaccggtcg 3420
ccaccatggt gagcaagggc gaggaggata acatggccat catcaaggag ttcatgcgct 3480
tcaaggtgca catggagggc tccgtgaacg gccacgagtt cgagatcgag ggcgagggcg 3540
agggccgccc ctacgagggc acccagaccg ccaagctgaa ggtgaccaag ggtggccccc 3600
tgcccttcgc ctgggacatc ctgtcccctc agttcatgta cggctccaag gcctacgtga 3660
agcaccccgc cgacatcccc gactacttga agctgtcctt ccccgagggc ttcaagtggg 3720
agcgcgtgat gaacttcgag gacggcggcg tggtgaccgt gacccaggac tcctccctgc 3780
aggacggcga gttcatctac aaggtgaagc tgcgcggcac caacttcccc tccgacggcc 3840
ccgtaatgca gaagaagacc atgggctggg aggcctcctc cgagcggatg taccccgagg 3900
acggcgccct gaagggcgag atcaagcaga ggctgaagct gaaggacggc ggccactacg 3960
acgctgaggt caagaccacc tacaaggcca agaagcccgt gcagctgccc ggcgcctaca 4020
acgtcaacat caagttggac atcacctccc acaacgagga ctacaccatc gtggaacagt 4080
acgaacgcgc cgagggccgc cactccaccg gcggcatgga cgagctgtac aagtaagaat 4140
tcgtcgaggg acctaataac ttcgtatagc atacattata cgaagttata catgtttaag 4200
ggttccggtt ccactaggta caattcgata tcaagcttat cgataatcaa cctctggatt 4260
acaaaatttg tgaaagattg actggtattc ttaactatgt tgctcctttt acgctatgtg 4320
gatacgctgc tttaatgcct ttgtatcatg ctattgcttc ccgtatggct ttcattttct 4380
cctccttgta taaatcctgg ttgctgtctc tttatgagga gttgtggccc gttgtcaggc 4440
aacgtggcgt ggtgtgcact gtgtttgctg acgcaacccc cactggttgg ggcattgcca 4500
ccacctgtca gctcctttcc gggactttcg ctttccccct ccctattgcc acggcggaac 4560
tcatcgccgc ctgccttgcc cgctgctgga caggggctcg gctgttgggc actgacaatt 4620
ccgtggtgtt gtcggggaaa tcatcgtcct ttccttggct gctcgcctgt gttgccacct 4680
ggattctgcg cgggacgtcc ttctgctacg tcccttcggc cctcaatcca gcggaccttc 4740
cttcccgcgg cctgctgccg gctctgcggc ctcttccgcg tcttcgcctt cgccctcaga 4800
cgagtcggat ctccctttgg gccgcctccc cgcatcgata ccgtcgacct cgatcgagac 4860
ctagaaaaac atggagcaat cacaagtagc aatacagcag ctaccaatgc tgattgtgcc 4920
tggctagaag cacaagagga ggaggaggtg ggttttccag tcacacctca ggtaccttta 4980
agaccaatga cttacaaggc agctgtagat cttagccact ttttaaaaga aaagggggga 5040
ctggaagggc taattcactc ccaacgaaga caagatatcc ttgatctgtg gatctaccac 5100
acacaaggct acttccctga ttggcagaac tacacaccag ggccagggat cagatatcca 5160
ctgacctttg gatggtgcta caagctagta ccagttgagc aagagaaggt agaagaagcc 5220
aatgaaggag agaacacccg cttgttacac cctgtgagcc tgcatgggat ggatgacccg 5280
gagagagaag tattagagtg gaggtttgac agccgcctag catttcatca catggcccga 5340
gagctgcatc cggactgtac tgggtctctc tggttagacc agatctgagc ctgggagctc 5400
tctggctaac tagggaaccc actgcttaag cctcaataaa gcttgccttg agtgcttcaa 5460
gtagtgtgtg cccgtctgtt gtgtgactct ggtaactaga gatccctcag acccttttag 5520
tcagtgtgga aaatctctag cagcatgtga gcaaaaggcc agcaaaaggc caggaaccgt 5580
aaaaaggccg cgttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa 5640
aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt 5700
ccccctggaa gctccctcgt gcgctctcct gttccgaccc tgccgcttac cggatacctg 5760
tccgcctttc tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc 5820
agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc 5880
gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccggtaag acacgactta 5940
tcgccactgg cagcagccac tggtaacagg attagcagag cgaggtatgt aggcggtgct 6000
acagagttct tgaagtggtg gcctaactac ggctacacta gaagaacagt atttggtatc 6060
tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa 6120
caaaccaccg ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa 6180
aaaggatctc aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa 6240
aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt 6300
ttaaattaaa aatgaagttt taaatcaatc taaagtatat atgagtaaac ttggtctgac 6360
agttaccaat gcttaatcag tgaggcacct atctcagcga tctgtctatt tcgttcatcc 6420
atagttgcct gactccccgt cgtgtagata actacgatac gggagggctt accatctggc 6480
cccagtgctg caatgatacc gcgagaccca cgctcaccgg ctccagattt atcagcaata 6540
aaccagccag ccggaagggc cgagcgcaga agtggtcctg caactttatc cgcctccatc 6600
cagtctatta attgttgccg ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc 6660
aacgttgttg ccattgctac aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca 6720
ttcagctccg gttcccaacg atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa 6780
gcggttagct ccttcggtcc tccgatcgtt gtcagaagta agttggccgc agtgttatca 6840
ctcatggtta tggcagcact gcataattct cttactgtca tgccatccgt aagatgcttt 6900
tctgtgactg gtgagtactc aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt 6960
tgctcttgcc cggcgtcaat acgggataat accgcgccac atagcagaac tttaaaagtg 7020
ctcatcattg gaaaacgttc ttcggggcga aaactctcaa ggatcttacc gctgttgaga 7080
tccagttcga tgtaacccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc 7140
agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg 7200
acacggaaat gttgaatact catactcttc ctttttcaat attattgaag catttatcag 7260
ggttattgtc tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg 7320
gttccgcgca catttccccg aaaagtgcca cctgacgtcg acggatcggg agatctcccg 7380
atcccctatg gtgcactctc agtacaatct gctctgatgc cgcatagtta agccagtatc 7440
tgctccctgc ttgtgtgttg gaggtcgctg agtagtgcgc gagcaaaatt taagctacaa 7500
caaggcaagg cttgaccgac aattgcatga agaatctgct tagggttagg cgttttgcgc 7560
tgcttcgcga tgtacgggcc agatatacgc gtt 7593
Claims (20)
1.一种T淋巴细胞,其特征在于,所述T淋巴细胞的Nur77被沉默;
以及表达嵌合抗原受体,其中,
所述嵌合抗原受体包括:
胞外区,所述胞外区包括单链抗体的重链可变区和轻链可变区,所述单链抗体特异性识别抗原CD19;
跨膜区,所述跨膜区与所述胞外区相连,并且嵌入到所述T淋巴细胞的细胞膜中;
胞内区,所述胞内区与所述跨膜区相连,并且所述胞内区包括CD28的胞内段以及CD3ζ链。
2.一种慢病毒,其特征在于,所述慢病毒携带下列核酸分子:
编码嵌合抗原受体的核酸分子,所述嵌合抗原受体具有SEQ ID NO:1所示的氨基酸序列,所述编码嵌合抗原受体的核酸分子具有SEQ ID NO:2所示的核苷酸序列;以及
任选地,沉默Nur77的核酸分子,所述沉默Nur77的核酸分子的核苷酸序列为选自SEQID NO:3~6的至少之一;
优选地,所述沉默Nur77的核酸分子的核苷酸序列为选自SEQ ID NO:3的至少之一。
3.一种慢病毒,其特征在于,所述慢病毒携带含有SEQ ID NO:7或8所示的核苷酸序列。
4.一种转基因淋巴细胞,其特征在于,所述淋巴细胞细胞Nur77被沉默;以及表达嵌合抗原受体,所述嵌合抗原受体包括:
胞外区,所述胞外区包括抗体的重链可变区和轻链可变区,所述抗体能够与肿瘤抗原特异性结合;
跨膜区;以及
胞内区,所述胞内区包括免疫共刺激分子胞内段,
其中,所述抗体为单链抗体,所述肿瘤抗原为CD19。
5.根据权利要求4所述的转基因淋巴细胞,其特征在于,所述淋巴细胞Nur77被沉默是通过shRNA、反义核酸、核酶、显性负突变、CRISPR和锌指核酸酶至少之一实现的。
6.根据权利要求4所述的转基因淋巴细胞,其特征在于,所述免疫共刺激分子胞内段独立地选自4-1BB、OX-40、CD40L、CD27、CD30、CD28以及他们的衍生物的至少一种。
7.根据权利要求5所述的转基因淋巴细胞,其特征在于,所述淋巴细胞细胞Nur77被沉默是通过shRNA实现的。
8.根据权利要求6所述的转基因淋巴细胞,其特征在于,所述免疫共刺激分子胞内段是4-1BB或CD28的胞内段。
9.根据权利要求4所述的转基因淋巴细胞,其特征在于,所述淋巴细胞是CD3+T淋巴细胞。
10.根据权利要求4所述的转基因淋巴细胞,其特征在于,所述淋巴细胞是自然杀伤细胞。
11.根据权利要求4所述的转基因淋巴细胞,其特征在于,所述淋巴细胞是自然杀伤T细胞。
12.一种构建体,其特征在于,所述构建体包括:
第一核酸分子,所述第一核酸分子编码嵌合抗原受体;以及
第二核酸分子,所述第二核酸分子沉默Nur77,其中,所述嵌合抗原受体是如权利要求4、6、8任一项中所定义的。
13.根据权利要求12所述的构建体,其特征在于所述第一核酸分子与所述第二核酸分子被设置在权利要求4~11任一项所述的淋巴细胞中表达所述嵌合抗原受体和沉默Nur77。
14.根据权利要求12所述的构建体,其特征在于,进一步包括:
第一启动子,所述第一启动子与所述第一核酸分子可操作地连接;以及
第二启动子,所述第二启动子与所述第二核酸分子可操作地连接。
15.根据权利要求14所述的构建体,其特征在于,所述第一启动子和所述第二启动子分别独立地选自U6,H1,CMV,EF-1,LTR或RSV启动子。
16.根据权利要求12所述的构建体,其特征在于,所述构建体的载体是非致病性病毒载体。
17.根据权利要求12所述的构建体,其特征在于,所述病毒载体包括选自反转录病毒载体、慢病毒载体或腺病毒相关病毒载体的至少之一。
18.一种制备权利要求1所述的T淋巴细胞或者权利要求4~11任一项所述的转基因淋巴细胞的方法,其特征在于,包括:
将权利要求12~17任一项所述的构建体或者权利要求2或3所述的慢病毒引入到淋巴细胞中或者T淋巴细胞。
19.一种用于治疗癌症的治疗组合物,其特征在于,包括:
权利要求12~17任一项所述的构建体、权利要求2或3所述的慢病毒、权利要求1所述的T淋巴细胞或者权利要求4~11任一项所述的转基因淋巴细胞。
20.根据权利要求19所述的治疗组合物,其特征在于,所述癌症包括选自造血系统恶性肿瘤和淋巴瘤的至少之一。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010195202.1A CN111518771A (zh) | 2020-03-19 | 2020-03-19 | 共表达抗CD19嵌合抗原受体和Nur77抑制分子的转基因淋巴细胞及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010195202.1A CN111518771A (zh) | 2020-03-19 | 2020-03-19 | 共表达抗CD19嵌合抗原受体和Nur77抑制分子的转基因淋巴细胞及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111518771A true CN111518771A (zh) | 2020-08-11 |
Family
ID=71900414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010195202.1A Pending CN111518771A (zh) | 2020-03-19 | 2020-03-19 | 共表达抗CD19嵌合抗原受体和Nur77抑制分子的转基因淋巴细胞及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111518771A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108342360A (zh) * | 2017-01-25 | 2018-07-31 | 北京马力喏生物科技有限公司 | 共表达抗msln嵌合抗原受体和无功能egfr的转基因淋巴细胞及其用途 |
CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
-
2020
- 2020-03-19 CN CN202010195202.1A patent/CN111518771A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108342360A (zh) * | 2017-01-25 | 2018-07-31 | 北京马力喏生物科技有限公司 | 共表达抗msln嵌合抗原受体和无功能egfr的转基因淋巴细胞及其用途 |
CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
Non-Patent Citations (1)
Title |
---|
JOYCE CHEN等: "NR4A transcription factors limit CAR T cell function in solid tumours", 《NATURE》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020201190B2 (en) | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency | |
CA2781332C (en) | System for increasing gene expression and vector comprising the system | |
KR20210068485A (ko) | 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍 | |
KR20220066914A (ko) | 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료 | |
CN111269888B (zh) | 一种adipsin基因修饰的脂肪干细胞、制备方法及其应用 | |
CN114591989B (zh) | 融合rna及其外泌体递送系统 | |
CN111926042B (zh) | 一种树突状细胞制剂及其应用 | |
CN117715660A (zh) | 右心室致心律失常性心肌病的基因治疗组合物和治疗 | |
CN108884446A (zh) | 基于aav的条件表达系统 | |
CN114107390B (zh) | 一种用于表达抗体IgG1的rAAV载体及其应用 | |
KR20230135086A (ko) | 막 결합된 인터류킨 15를 갖는 종양 침윤성 림프구및 이의 용도 | |
KR20210095586A (ko) | off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물 | |
KR101885438B1 (ko) | 유전자치료 벡터시스템 및 전구약물 유전자 | |
KR20200003160A (ko) | 조혈모세포의 형질도입을 위한 개선된 렌티바이러스 | |
CN111518771A (zh) | 共表达抗CD19嵌合抗原受体和Nur77抑制分子的转基因淋巴细胞及其用途 | |
CN109321587B (zh) | 一种acat1基因干扰的嵌合抗原受体t细胞 | |
CN112301058B (zh) | 一种重组腺相关病毒载体及其制备方法与应用 | |
CN104403998A (zh) | 一种用于表皮损伤修复的改良式脂肪干细胞 | |
CN109735558B (zh) | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 | |
US20020103144A1 (en) | Retroviral gene transfer vectors | |
CN115335523A (zh) | 分子系统和使用该系统的疗法 | |
CN109097333B (zh) | 抵抗细胞衰老及延长血糖调节作用时程的间充质干细胞及其制备方法和用途 | |
CN114164185A (zh) | 一种基于黑猩猩腺病毒表达spike蛋白的新型冠状病毒疫苗 | |
CN113710809A (zh) | 通过基因置换和抗炎的针对杜氏肌营养不良的一步基因疗法 | |
CN115667536A (zh) | 用于巴尔得-别德尔综合征的基因治疗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200811 |
|
RJ01 | Rejection of invention patent application after publication |